Cargando…
Impact of concomitant fibrates on immunotherapy outcomes for advanced non‐small cell lung cancer
BACKGROUND: Peroxisome proliferator‐activated receptor agonists such as fibrates restore oxidative metabolism in cytotoxic T‐lymphocytes, thereby enhancing response to immune checkpoint inhibitors (ICI) in preclinical models. However, there is no evidence in humans on the clinical impact of fibrates...
Autores principales: | Stokes, William A., Behera, Madhusmita, Jiang, Renjian, Gutman, David A., Huang, Zhonglu, Burns, Abigail, Sebastian, Nikhil T., Sukhatme, Vidula, Lowe, Michael C., Ramalingam, Suresh S., Sukhatme, Vikas P., Moghanaki, Drew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844615/ https://www.ncbi.nlm.nih.gov/pubmed/35607930 http://dx.doi.org/10.1002/cam4.4847 |
Ejemplares similares
-
Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014) -
Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2015) -
Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016) -
Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014) -
Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent
por: Sukhatme, Vidula, et al.
Publicado: (2015)